Mizuho Lowers LifeMD (NASDAQ:LFMD) Price Target to $6.00

LifeMD (NASDAQ:LFMD) had its price target dropped by investment analysts at Mizuho from $8.00 to $6.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s target price would suggest a potential upside of 50.00% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. KeyCorp cut their target price on shares of LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. BTIG Research lowered their target price on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Finally, Lake Street Capital cut their price target on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

LifeMD Stock Down 2.2%

LifeMD stock opened at $4.00 on Wednesday. The company has a debt-to-equity ratio of 9.21, a quick ratio of 0.72 and a current ratio of 0.77. The firm has a market capitalization of $189.67 million, a price-to-earnings ratio of -23.54 and a beta of 1.57. LifeMD has a fifty-two week low of $3.43 and a fifty-two week high of $15.84. The stock’s fifty day moving average is $6.01 and its two-hundred day moving average is $8.68.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, November 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same period in the previous year, the business earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that LifeMD will post -0.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares of the company’s stock, valued at $3,581,600. This represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 18.40% of the company’s stock.

Hedge Funds Weigh In On LifeMD

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in LifeMD by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock worth $15,120,000 after buying an additional 140,749 shares during the last quarter. Royce & Associates LP increased its stake in shares of LifeMD by 3.5% during the 1st quarter. Royce & Associates LP now owns 1,155,231 shares of the company’s stock valued at $6,284,000 after acquiring an additional 39,240 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of LifeMD by 5.4% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company’s stock worth $5,342,000 after acquiring an additional 50,600 shares during the period. Geode Capital Management LLC boosted its position in shares of LifeMD by 7.9% in the second quarter. Geode Capital Management LLC now owns 925,173 shares of the company’s stock worth $12,603,000 after acquiring an additional 67,440 shares during the last quarter. Finally, Jump Financial LLC grew its holdings in LifeMD by 205.0% in the second quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock valued at $7,015,000 after purchasing an additional 346,171 shares during the period. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.